Who is sponsoring NCT02532998?

NCT02532998 is sponsored by AstraZeneca.

What condition does NCT02532998 study?

NCT02532998 studies Pharmacodynamics, Healthy Subjects.

What drugs are being tested in NCT02532998?

Interventions: AZD9977 oral suspension, AZD9977 placebo oral suspension, Fludrocortisone, tablets, Eplerenone, tablets.

What is the status of NCT02532998?

NCT02532998 is currently COMPLETED.

Last reviewed 2017-02-09 · How we verify

A Phase I, Randomized, Single-Blind, Crossover Study to Assess the Pharmacodynamics of AZD9977 Following Single-Dose Administration to Healthy Male Subjects

NCT02532998 Phase 1 COMPLETED Results posted

This is a Phase I, Randomized, Single-Blind, Crossover Study to Assess the Pharmacodynamics of AZD9977 following Single-Dose administration to healthy male subjects

Details

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	COMPLETED
Enrolment	40
Start date	2015-09
Completion	2015-12

Conditions

Pharmacodynamics
Healthy Subjects

Interventions

AZD9977 oral suspension
AZD9977 placebo oral suspension
Fludrocortisone, tablets
Eplerenone, tablets

Primary outcomes

Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in Eplerenone Treatment Versus a Combination Treatment of Eplerenone and AZD9977. — From 2 hours post dose to 8 hours post dose
The sum over the urine collection intervals of the logarithm of the urinary sodium/potassium ratio from two hours to eight hours post-dose. NOTE: Data are presented as the sum of the difference between ln(Na+) and ln(K+) over the collected intervals 2-4, 4-6 and 6-8 hours.

Countries

United Kingdom